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Abstract
Previous studies have reported very different rates of human rhinovirus (HRV) and respiratory syncytial virus (RSV)
genome detection in nasal and sputum samples, but not in bronchoalveolar lavage (BAL) and bronchial biopsy
samples. Our study aimed to investigate the presence of HRV and RSV in the lungs of 31 consecutive patients with
stable COPD (11 GOLD stage I, 11 II, and 9 III) and 22 control subjects (12 current or past smokers, and 10
non-smokers), who underwent diagnostic (e.g., lung cancer) and/or therapeutic (e.g., hemoptysis) fibreoptic
bronchoscopy in a university hospital in Athens, Greece. Viral RNA of HRV and RSV were not detected in any of
the samples of COPD patients or control subjects after being processed with real-time PCR.
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Findings
Background
The potential role of persistent low-grade, latent viral infec-
tion in disease progression in stable COPD is a matter of
great importance [1, 2] and controversy partly due to differ-
ences in the reported occurrence of asymptomatic virus in-
fection in COPD. Indeed, in the study by Seemungal et al.
[3] HRV and RSV were detected in blood samples/nasal as-
pirates in 7,4 and 23,5 % of patients with stable COPD,
respectively, whereas in the study by Falsey et al [4] nasal
and sputum samples were positive for RSV in only 0 and
0,9 %, respectively. Importantly, none of the previous stud-
ies evaluated samples coming directly from the lower air-
ways, i.e., bronchoalveolar lavage (BAL) fluid or bronchial
biopsies, which are fully representative of the lower respira-
tory tract. Nevertheless, it is constantly stressed out that
further studies across the spectrum of disease as well as in
smoking and non smoking control subjects are required to
better understand the role of asymptomatic viral infection
in stable COPD [1, 2].
Therefore, the aim of this study was to investigate
whether HRV and RSV are present in the lungs of stable
COPD patients by performing BAL and bronchial biop-
sies, and relate their presence with disease severity.
Methods
The population of the study consisted of consecutive pa-
tients with stable COPD and control subjects (non-
smokers or current/ex-smokers), who were referred to the
Sismanoglion Hospital, Athens, Greece, between October
2012 and November 2014 in order to undergo fibreoptic
bronchoscopy for diagnostic (e.g., lung cancer) or thera-
peutic (e.g., hemoptysis) purposes. At study time, the clin-
ical and functional status of COPD patients had been
stable for at least 4 weeks [5], and none had received anti-
biotic treatment during the last 4 weeks. Exclusion criteria
included atopic history, asthma, extensive pleural effusions,
bronchiectasis, immunosuppression due to chemotherapy
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or systemic corticosteroids and all the contraindications of
the bronchoscopic procedures.
All the participants completed a questionnaire which in-
cluded demographic characteristics, cigarette smoking sta-
tus (pack/year) and their past medical history. Τheir clinical
status was evaluated according to the modified Medical Re-
search Council (mMRC) scale of breathlessness and the
Body mass, airflow Obstruction, Dyspnea, Exercise (BODE)
index. Pulmonary function testing was performed, and
arterial blood gases and blood oxygen saturation by pulse
oximetry in the sitting position were measured. We per-
formed BAL from subsegmental bronchi and bronchial bi-
opsies (3–4 per patient) from non infiltrated carina. RNA
samples were extracted from BAL and lung biopsies and a
nucleocapsid (N) gene partial sequence, as well as a 5’ non-
coding region (5΄NCR) partial sequence were amplified for
RSV and HRV, respectively. Real-time PCR studies were
performed in Stratagene Mx3005 Real-Time PCR Instru-
ment (Agilent Technologies, Santa Clara, CA, USA). The
primer and probe mix provided exploited the so-called Taq-
Man principle. Each time the kits were used, a positive and
a negative control reaction were included in the run.
The study was approved by the local Medical Ethics
Committee of Sismanoglion Hospital and all subjects
gave their informed consent.
Results
We enrolled 31 patients with COPD and 22 control sub-
jects. The most common symptoms were dyspnea (32 %),
cough (19 %) and hemoptysis (13 %). Whereas 47 % of
participants did not mention any symptom, but referred
to our department in order to investigate bronchoscopi-
cally abnormal radiographic findings revealed in chest
computed tomography. We diagnosed lung cancer in
63,6 % of control subjects (adenocarcinoma: 4, squamous
cell carcinoma: 9, small cell carcinoma:1), and in 67,7 % of
COPD patients (adenocarcinoma:7, squamous cell carcin-
oma: 8, small cell carcinoma: 6). The commonest comor-
bidities of COPD patients were arterial hypertension
(47 %), hyperlipidemia (20.7 %) and coronary artery dis-
ease (17 %), and of control subjects arterial hypertension
(50 %), hyperlipidemia (22,7 %) and diabetes mellitus type
2 (13,6 %).
Anthropometric characteristics and lung function data
of both COPD patients and control subjects are shown in
Table 1. Controls and COPD patients had comparable age,
FVC, DLCO and PaCO2. As expected, COPD patients had
lower spirometric values, arterial blood gases measure-
ments and higher rate of smoking habits, mMRC scale
and BODE index scores compared to control subjects.
All BAL and bronchial biopsy samples (53 and 181, re-
spectively) were processed for the detection of HRV and
RSV genome with real-time PCR. In Fig.1a and b we can
see representative amplification plots for HRV and RSV,
respectively.
In all amplification plots for HRV and RSV, samples’
and negative controls’ fluorescence signals were at the
same level indicating that these two viruses were not de-
tected in any of the samples of COPD patients and con-
trol subjects.
Discussion
There are sparse publications and controversial reports
concerning viral infection of the respiratory tract in stable
COPD [1, 3, 4, 6]. Our study had several limitations that
Table 1 Anthropometric characteristics and respiratory function
data of COPD patients and control subjects
Parameters COPD Controls
(n = 31) (n = 22)
Gender, Males (%) 26 (83,8 %) 16 (72,7 %)
Age, years 67.6 ± 8.1 62.4 ± 11.7
BMI, kg/m2 25.3 ± 4.6** 25.7 ± 4.5
Pack/Years 57 ± 27* 35.45 ± 35
FVC, % pred 85.6 ± 20.1 93.6 ± 15.9
FEV1, % pred 70.8 ± 18.6*** 93.3 ± 15.9
FEV1/FVC, % 63.7 ± 8.04*** 78.9 ± 5.28
Spirometric classification of COPD:
I, II, III, IV
11,11,9,0 NA
PEF, % pred 69.4 ± 20* 87 ± 23
DLCO, % pred 72.1 ± 25.5 85 ± 22.8
SpO2, % 94.7 ± 3.2* 96.45 ± 1.2
PaO2, mmHg 70.2 ± 12.1* 79.57 ± 6.47
PaCO2, mmHg 38 ± 2.25 40.1 ± 1.7




Symptom/risk evaluation of COPD:
A, B, C, D
19,3,4,5 NA




Inhaled steroids, n (%) 4(7.5 %) 0(0)
Values are means (±SD)
Abbreviations: BMI body mass index; FVC forced vital capacity; FEV1 forced
expiratory volume in one second; NA Non Applicable; PEF peak expiratory
flow; DLCO diffusing capacity of the lung for carbon monoxide; SpO2 % arterial
oxygen saturation measured with pulse arterial oximeter; PaO2 partial arterial
oxygen tension (at room air); PaCO2 partial arterial carbon dioxide tension;
mMRC modified Medical Research Council scale (0: not troubled by
breathlessness except on strenuous exercise, 1: shortness of breath when
hurrying on the level or walking up a slight hill, 2: walks slower than people of
the same age on the level because of breathlessness or has to stop for breath
when walking at own pace on the level, 3: stops for breath after walking
about 100 m or after a few minutes on the level, 4: too breathless to leave the
house or breathless when dressing or undressing); Symptom/risk COPD
evaluation: A = Low risk-Less symptoms/B = Low risk-More symptoms/C = High
risk-Less symptoms/D = High risk-More symptoms; BODE index: Body mass
index (kg/m2), airflow Obstruction (FEV1% pred), Dyspnea (mMRC scale),
Exercise (6 min walking distance) (0–2 points: 80 % 4 year survival, 3–4: 67 %,
5–6: 57 %, 7–10: 18 %)
*p < 0.05 compared with controls; **p < 0.01 compared with controls; ***p < 0.001
compared with controls
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probably influenced the results. More specifically, we in-
cluded patients from 3 of the 4 GOLD stages as it was
rather difficult to perform bronchoscopy in patients with
very severe COPD. This could have an impact on our re-
sults as the relative importance of airway bacterial infec-
tion in COPD has been shown to increase with disease
severity [7]. Also, most of the COPD patients did not ex-
perience any exacerbations during the year before recruit-
ment, while there is a tendency for patients in whom HRV
and RSV are detected in stable COPD to give a history of
more frequent exacerbations in the previous year [3].
Additionally, the number of participants in the study was
relatively small, and the enrollment of patients was per-
formed in only one center.
On the other hand, the detection rates for HRV and
RSV among the two groups of normal control subjects
and the results were zero, which is similar to previous re-
ports [8, 9]. In addition to this, the majority of our partici-
pants did not use inhaled and oral corticosteroids on a
chronic basis. This is very important as prolonged shed-
ding of RSV has been described in a number of immuno-
suppressive conditions such as corticosteroid use and
HIV infection [10]. The PCR kits that we used are de-
signed to have the broadest detection profile possible
whilst remaining specific to the HRVsp and to the
RSV_spp genome. We ensured that the samples were
suitable in terms of purity, concentration, and RNA/
DNA integrity and we always run at least one negative
control with the samples. An alternative explanation for
the discrepancy between this study and previous re-
ports is the possibility of PCR contamination which
leads to high rates of HRV and RSV RNA identification
in subjects with stable COPD.
In conclusion, we have shown for the first time using
bronchoscopy that both HRV and RSV RNA were not
detected in the BAL and bronchial biopsy samples col-
lected from patients with stable COPD and from control
subjects. The possibility of chronic HRV and RSV infec-
tion as a mechanism of disease progression could have
enormous impact on the management of the disease but
our study does not support this hypothesis.
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Fig. 1 a Representative amplification plot for HRV. Horizontal blue line: baseline of the method. Curved blue line: positive control. Remaining
lines: negative controls and samples. b Representative amplification plot for RSV. Horizontal blue line: baseline of the method. Curved blue line:
positive control. Remaining lines: negative controls and samples
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